PHOENIX BRAIN RESEARCH CIC

Company Registration Number:
12953439 (England and Wales)

Unaudited statutory accounts for the year ended 31 March 2025

Period of accounts

Start date: 1 April 2024

End date: 31 March 2025

PHOENIX BRAIN RESEARCH CIC

Contents of the Financial Statements

for the Period Ended 31 March 2025

Directors report
Profit and loss
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

PHOENIX BRAIN RESEARCH CIC

Directors' report period ended 31 March 2025

The directors present their report with the financial statements of the company for the period ended 31 March 2025

Principal activities of the company

The company did not trade throughout the year



Directors

The directors shown below have held office during the whole of the period from
1 April 2024 to 31 March 2025

Dr D S Allen
Dr M Stoffels


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
23 December 2025

And signed on behalf of the board by:
Name: Dr D S Allen
Status: Director

PHOENIX BRAIN RESEARCH CIC

Profit And Loss Account

for the Period Ended 31 March 2025

2025 2024


£

£
Turnover: 0 0
Gross profit(or loss): 0 0
Administrative expenses: ( 1,635 ) ( 1,366 )
Operating profit(or loss): (1,635) (1,366)
Profit(or loss) before tax: (1,635) (1,366)
Profit(or loss) for the financial year: (1,635) (1,366)

PHOENIX BRAIN RESEARCH CIC

Balance sheet

As at 31 March 2025

Notes 2025 2024


£

£
Current assets
Debtors: 3 30 100
Cash at bank and in hand: 15 110
Total current assets: 45 210
Creditors: amounts falling due within one year: 4 ( 6,237 ) ( 4,767 )
Net current assets (liabilities): (6,192) (4,557)
Total assets less current liabilities: (6,192) ( 4,557)
Total net assets (liabilities): (6,192) (4,557)
Capital and reserves
Called up share capital: 100 100
Profit and loss account: (6,292 ) (4,657 )
Total Shareholders' funds: ( 6,192 ) (4,557)

The notes form part of these financial statements

PHOENIX BRAIN RESEARCH CIC

Balance sheet statements

For the year ending 31 March 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 23 December 2025
and signed on behalf of the board by:

Name: Dr D S Allen
Status: Director

The notes form part of these financial statements

PHOENIX BRAIN RESEARCH CIC

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Other accounting policies

    Basis of preparing the financial statements The financial statements have been prepared under the historical cost convention. The accounts have been prepared on a going concern basis notwithstanding the net liability currently shown on the balance sheet. The directors have confirmed their intention to support the company for at least the next 12 months. Taxation Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. Current or deferred taxation assets and liabilities are not discounted. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. Deferred tax Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Financial instruments Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the entity after deducting all of its financial liabilities. Where the contractual obligations of financial instruments (including share capital) are equivalent to a similar debt instrument, those financial instruments are classed as financial liabilities. Financial liabilities are presented as such in the balance sheet. Finance costs and gains or losses relating to financial liabilities are included in the profit and loss account. Finance costs are calculated so as to produce a constant rate of return on the outstanding liability. Where the contractual terms of share capital do not have any terms meeting the definition of a financial liability then this is classed as an equity instrument. Dividends and distributions relating to equity instruments are debited direct to equity

PHOENIX BRAIN RESEARCH CIC

Notes to the Financial Statements

for the Period Ended 31 March 2025

  • 2. Employees

    2025 2024
    Average number of employees during the period 2 2

PHOENIX BRAIN RESEARCH CIC

Notes to the Financial Statements

for the Period Ended 31 March 2025

3. Debtors

2025 2024
£ £
Other debtors 30 100
Total 30 100

PHOENIX BRAIN RESEARCH CIC

Notes to the Financial Statements

for the Period Ended 31 March 2025

4. Creditors: amounts falling due within one year note

2025 2024
£ £
Accruals and deferred income 1,046 995
Other creditors 5,191 3,772
Total 6,237 4,767

COMMUNITY INTEREST ANNUAL REPORT

PHOENIX BRAIN RESEARCH CIC

Company Number: 12953439 (England and Wales)

Year Ending: 31 March 2025

Company activities and impact

THE COMPANY HAS MADE AN APPLICATION TO NIHR FOR A GRANT TOWARDS A RESEARCH PROJECT IN PARTNERSHIP WITH THE UNIVERSITY OF WESTMINSTER (WORTH IN TOTAL CIRCA £1.4MILLION) TO TEST THE EFFICACY OF AN APP TO MONITOR NUTRITION IN ADULTS WITH ADHD DEPENDENT ON THEIR NUTRIGENOMIC STATUS. WE EXPECT TO HEAR IF WE HAVE BEEN SUCCESSFUL NEXT FINANCIAL YEAR.

Consultation with stakeholders

DR DANIEL ALLEN HAS BEEN ACTIVELY INVOLVED IN DISCUSSIONS WITH THE FOLLOWING STAKEHOLDERS: PHOENIX MENTAL HEALTH SERVICES LLP PSYCHIATRY UK LTD THE UNIVERSITY OF WESTMINSTER

Directors' remuneration

No remuneration was received

Transfer of assets

No transfer of assets other than for full consideration

This report was approved by the board of directors on
23 December 2025

And signed on behalf of the board by:
Name: Daniel Allen
Status: Director